Antibodies and immunoconjugates and uses therefor

Abstract

Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.

1 - 238 . (canceled) 
     
     
         239 . A variable domain of an anti-CD22 antibody comprising a heavy chain variable domain amino acid sequence of SEQ ID NO: 16. 
     
     
         240 . A variable domain of an anti-CD22 antibody comprising a light chain variable domain amino acid sequence of SEQ ID NO: 18. 
     
     
         241 . An anti-CD22 antibody comprising the heavy chain variable domain sequence of SEQ ID NO: 18 and the light chain variable domain sequence of SEQ ID NO: 16. 
     
     
         242 . An anti-CD22 antibody having a variable light chain comprising a HVR-L1 having the sequence of SEQ ID NO: 10, a HVR-L2 having the sequence of SEQ ID NO: 12, and a HVR-L3 having the sequence of SEQ ID NO: 14. 
     
     
         243 . An anti-CD22 antibody having a variable heavy chain comprising a HVR-H1 having the sequence of SEQ ID NO: 2, a HVR-H2 having the sequence of SEQ ID NO: 4, and a HVR-H3 having the sequence of SEQ ID NO: 6. 
     
     
         244 . A polypeptide comprising the amino acid sequence of SEQ ID NO: 16. 
     
     
         245 . A polypeptide comprising the amino acid sequence of SEQ ID NO: 18. 
     
     
         246 . An antibody fragment of  claim 242  or  243 . 
     
     
         247 . A composition comprising the antibody of  claim 242  or  243 . 
     
     
         248 . Use of the composition of  claim 244  to treat a B cell proliferative disorder. 
     
     
         249 . The use according to  claim 245 , wherein the disorder is selected from the group consisting of lymphoma, non-Hogkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma. 
     
     
         250 . The antibody of  claim 242  or  243  wherein the antibody is selected from a monoclonal antibody, a bispecific antibody, a chimeric antibody, a human antibody or a humanized antibody.